Screening Possible Substrates of E3 Ligase RNF19A by Immunofluorescence Staining

Stephanie Oseakhumen Emhenya

doi:10.54254/2753-8818/2025.AU27338

Theoretical and Natural ScienceOpen access

Screening Possible Substrates of E3 Ligase RNF19A by Immunofluorescence Staining

Research Article

Open Access

Screening Possible Substrates of E3 Ligase RNF19A by Immunofluorescence Staining

Stephanie Oseakhumen Emhenya ^1*

¹ Basis International School Guangzhou

^*Corresponding author: stephanieemhenya1@gmail.com

Published on 2 October 2025

TNS Vol.139

ISSN (Print): 2753-8826

ISSN (Online): 2753-8818

ISBN (Print): 978-1-80590-395-6

ISBN (Online): 978-1-80590-396-3

Download Cover

Abstract

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer and one of the most common and deadly cancers in women. The incidence of TNBC is high globally, but there are few treatment options, and chemotherapy remains the primary treatment method for TNBC patients. Research found that ubiquitination is a potential target that can help provide better treatment to multiple cancers including TNBC. However the role of ubiquitinationin cancer is not very clear. Thus, more in-depth research is needed to create better treatment for TNBC patients. An bioinformatics analysis was conducted to identify potential substrates for the E3 ligase RNF19A. Immunofluorescence staining was utilized to compare the co-localization of RNF19A with these potential substrates in A549 and MDA-MB-231 cell lines. Then TP53 activator PRIMA-1 and the SOD1 inhibitor ATN-224 to was added to observe the fluorescence intensity of RNF19A. The findings revealed the RNF19A can affect the fluorescence intensity of subcellular localization of TP53 in MDA-MB-231 cells. The differential effects were also noted in A549cells. In contrast, treatment with the SOD1 inhibitor resulted in decreased fluorescence in A549 cells, indicating a specific pathway involvement in non-small cell lung cancer (NSCLC) rather than TNBC. This study demonstrates that fluorescence intensity of RNF19A is impacted by the addition of the activator and the inhibitor of TP53. The RNF19A can potentially contribute to the understanding of its function in cancer-related cellular processes. These findings provide a foundational basis for exploring RNF19A as a potential therapeutic target in conditions like TNBC, marked by aberrant protein localization and function

Keywords:

TNBC, RNF19A, Ubiquitination, Immunofluorescence

View PDF

References

[1]. M.S. Moran, Radiation therapy in the locoregional treatment of triple-negative breast cancer, The Lancet. Oncology 16(3) (2015) e113-22.

[2]. A.N. Giaquinto, H. Sung, L.A. Newman, R.A. Freedman, R.A. Smith, J. Star, A. Jemal, R.L. Siegel, Breast cancer statistics 2024, CA: a cancer journal for clinicians 74(6) (2024) 477-495.

[3]. G. Bianchini, C. De Angelis, L. Licata, L. Gianni, Treatment landscape of triple-negative breast cancer - expanded options, evolving needs, Nature reviews. Clinical oncology 19(2) (2022) 91-113.

[4]. Y. Hu, C. Wang, H. Liang, J. Li, Q. Yang, The treatment landscape of triple-negative breast cancer, Medical oncology (Northwood, London, England) 41(10) (2024) 236.

[5]. A.M. Karim, J. Eun Kwon, T. Ali, J. Jang, I. Ullah, Y.G. Lee, D.W. Park, J. Park, J.W. Jeang, S.C. Kang, Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies, Biochemical pharmacology 212 (2023) 115545.

[6]. S. Dawood, Triple-negative breast cancer: epidemiology and management options, Drugs 70(17) (2010) 2247-58.

[7]. I. Susumu, I. Kiyotaka, S. Shinichi, U. Keiji, H. Naoki, Y. Hiromasa, T. Yoshinori, Benefits of terminal noncardioplegic warm blood retrograde perfusion after terminal warm blood cardioplegia perfusion prior to aortic unclamping in open heart surgery, The Journal of cardiovascular surgery 47(6) (2006) 677-82.

[8]. D.H. Schlesinger, G. Goldstein, H.D. Niall, The complete amino acid sequence of ubiquitin, an adenylate cyclase stimulating polypeptide probably universal in living cells, Biochemistry 14(10) (1975) 2214-8.

[9]. D.H. Schlesinger, G. Goldstein, Molecular conservation of 74 amino acid sequence of ubiquitin between cattle and man, Nature 255(5507) (1975) 423-4.

[10]. D. Popovic, D. Vucic, I. Dikic, Ubiquitination in disease pathogenesis and treatment, Nature medicine 20(11) (2014) 1242-53.

[11]. R. Kandel, J. Jung, S. Neal, Proteotoxic stress and the ubiquitin proteasome system, Seminars in cell & developmental biology 156 (2024) 107-120.

[12]. E. Rivkin, A.L. Kierszenbaum, M. Gil, L.L. Tres, Rnf19a, a ubiquitin protein ligase, and Psmc3, a component of the 26S proteasome, tether to the acrosome membranes and the head-tail coupling apparatus during rat spermatid development, Developmental dynamics : an official publication of the American Association of Anatomists 238(7) (2009) 1851-61.

[13]. C. Wu, Z. Su, M. Lin, J. Ou, W. Zhao, J. Cui, R.F. Wang, NLRP11 attenuates Toll-like receptor signalling by targeting TRAF6 for degradation via the ubiquitin ligase RNF19A, Nature communications 8(1) (2017) 1977.

[14]. Q. Zhu, J. Huang, H. Huang, H. Li, P. Yi, J.A. Kloeber, J. Yuan, Y. Chen, M. Deng, K. Luo, M. Gao, G. Guo, X. Tu, P. Yin, Y. Zhang, J. Su, J. Chen, Z. Lou, RNF19A-mediated ubiquitination of BARD1 prevents BRCA1/BARD1-dependent homologous recombination, Nature communications 12(1) (2021) 6653.

[15]. V.U. Bai, O. Hwang, G.W. Divine, E.R. Barrack, M. Menon, G.P. Reddy, C. Hwang, Averaged differential expression for the discovery of biomarkers in the blood of patients with prostate cancer, PloS one 7(4) (2012) e34875.

[16]. K. Im, S. Mareninov, M.F.P. Diaz, W.H. Yong, An Introduction to Performing Immunofluorescence Staining, Methods in molecular biology (Clifton, N.J.) 1897 (2019) 299-311.

[17]. H. Deng, G. Ji, J. Ma, J. Cai, S. Cheng, F. Cheng, RNF19A inhibits bladder cancer progression by regulating ILK ubiquitination and inactivating the AKT/mTOR signalling pathway, Biology direct 19(1) (2024) 102.

[18]. S. Zhu, M. Tao, Y. Li, X. Wang, Z. Zhao, Y. Liu, Q. Li, Q. Li, Y. Lu, Y. Si, S. Cao, J. Ye, H3K27me3 of Rnf19a promotes neuroinflammatory response during Japanese encephalitis virus infection, Journal of neuroinflammation 20(1) (2023) 168.

[19]. H. Zuo, J. Park, A. Frangaj, J. Ye, G. Lu, J.J. Manning, W.B. Asher, Z. Lu, G.B. Hu, L. Wang, J. Mendez, E. Eng, Z. Zhang, X. Lin, R. Grassucci, W.A. Hendrickson, O.B. Clarke, J.A. Javitch, A.D. Conigrave, Q.R. Fan, Promiscuous G-protein activation by the calcium-sensing receptor, Nature 629(8011) (2024) 481-488.

[20]. Q. Zhou, M.M. Zhang, M. Liu, Z.G. Tan, Q.L. Qin, Y.G. Jiang, LncRNA XIST sponges miR-199a-3p to modulate the Sp1/LRRK2 signal pathway to accelerate Parkinson's disease progression, Aging 13(3) (2021) 4115-4137.

[21]. R. Mohammad Malyar, H. Li, H. Enayatullah, L. Hou, R. Ahmad Farid, D. Liu, J. Akhter Bhat, J. Miao, F. Gan, K. Huang, X. Chen, Zinc-enriched probiotics enhanced growth performance, antioxidant status, immune function, gene expression, and morphological characteristics of Wistar rats raised under high ambient temperature, 3 Biotech 9(8) (2019) 291.

[22]. Y. Cheng, Y. Hu, H. Wang, Z. Zhao, X. Jiang, Y. Zhang, J. Zhang, Y. Tong, X. Qiu, Ring finger protein 19A is overexpressed in non-small cell lung cancer and mediates p53 ubiquitin-degradation to promote cancer growth, Journal of cellular and molecular medicine 25(16) (2021) 7796-7808.

[23]. P. Cohen, M. Tcherpakov, Will the ubiquitin system furnish as many drug targets as protein kinases?, Cell 143(5) (2010) 686-93.

[24]. E.C.A. Eleutherio, R.S. Silva Magalhães, A. de Araújo Brasil, J.R. Monteiro Neto, L. de Holanda Paranhos, SOD1, more than just an antioxidant, Archives of biochemistry and biophysics 697 (2021) 108701.

[25]. J. Niwa, S. Ishigaki, N. Hishikawa, M. Yamamoto, M. Doyu, S. Murata, K. Tanaka, N. Taniguchi, G. Sobue, Dorfin ubiquitylates mutant SOD1 and prevents mutant SOD1-mediated neurotoxicity, The Journal of biological chemistry 277(39) (2002) 36793-8.

[26]. L.J. Martin, S.J. Koh, A. Price, D. Park, B.W. Kim, Nuclear Localization of Human SOD1 in Motor Neurons in Mouse Model and Patient Amyotrophic Lateral Sclerosis: Possible Links to Cholinergic Phenotype, NADPH Oxidase, Oxidative Stress, and DNA Damage, International journal of molecular sciences 25(16) (2024).